Former employees of Astrazeneca are embroiled in a bitter dispute with the company following the collapse of a drugs manufacturing plant little more than two years after it was sold.
They have accused the FTSE 100 pharmaceuticals group of betrayal through failing to ensure payment of £12 million of enhanced redundancy pay, a lack of due diligence on the deal and circulating misleading information to staff ahead of it.
